Abstract:
:Polymerase chain reaction (PCR) techniques based on amplification and identification of leukemia-specific DNA sequences provide a sensitive diagnostic method for detection of minimal residual disease (MRD) with a detection limit of 10(-5) to 10(-6) (1-10 malignant cells in 10(6) normal cells). To date, the main leukemia-specific DNA sequences used as PCR targets in detection of MRD are breakpoint fusion regions of chromosome translocations and junctional regions of rearranged immunoglobulin (Ig) or T-cell receptor (TcR) genes. The recently identified tal-1 deletions involving the sil and tal-1 genes, provide a potential MRD-PCR target. tal-1 deletions are site-specific because they are mediated via recombination signal sequences homologous to Ig/TcR genes. In line with this homology, tal-1 deletions also show random insertion and deletion of nucleotides at their breakpoints, resulting in highly variable breakpoint fusion regions. The fusion region diversity can be applied to design patient-specific oligonucleotide probes. Our Southern blot analyses of a large series of 313 acute leukemias with a specific tal-1 deletion probe (SILDB) demonstrated that tal-1 deletions exclusively occur in T-cell acute lymphoblastic leukemia (T-ALL) and not in precursor B-ALL or acute non-lymphocytic leukemias. In addition, we did not detect tal-1 deletions in normal blood cells and normal thymocytes by PCR analysis. The diversity observed in tal-1 deletion fusion regions with an average insertion and deletion of approximately 7 and approximately 6 nucleotides, respectively, allowed us to design fusion-region-specific probes. The specificity of the fusion-region probes was proven and the detection limit of the MRD-PCR technique was tested in a series of dilution experiments. The observed detection limit of 10(-5) indicates that tal-1 deletions in T-ALL represent ideal leukemia-specific PCR targets for detection of MRD.
journal_name
Leukemiajournal_title
Leukemiaauthors
Breit TM,Beishuizen A,Ludwig WD,Mol EJ,Adriaansen HJ,van Wering ER,van Dongen JJsubject
Has Abstractpub_date
1993-12-01 00:00:00pages
2004-11issue
12eissn
0887-6924issn
1476-5551journal_volume
7pub_type
杂志文章相关文献
LEUKEMIA文献大全abstract::Therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML) are serious complications of chemotherapy and radiotherapy for cancer. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be associated with an increased incidence of these complications. The frequency o...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402631
更新日期:2002-09-01 00:00:00
abstract::Graft-versus-host disease (GVHD) remains a major immunological complication after allogeneic bone marrow transplantation (allo-BMT), but also favors development of the beneficial graft-versus-leukemia (GVL) effect. A patient with AML-M4 (inv (16)) is described, who was given non-myeloablative remission reinduction the...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400810
更新日期:1997-10-01 00:00:00
abstract::This study demonstrates that the human bone marrow mononuclear cell fraction that adheres to plastic during a 2-h incubation period includes stromal precursors and hematopoietic progenitor cells that can sustain hematopoiesis for at least 5 weeks in a long-term culture (LTC) system. Delta (delta) assays were performed...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-05-01 00:00:00
abstract::The human immunoglobulin lambda (Ig(lambda)) gene locus contains seven homologous C(lambda) exons which are organized in a tandem array, each of which is preceded by a single J(lambda) gene segment. The J-C(lambda)1, J-C(lambda)2, J-C(lambda)3, and J-C(lambda)7 are functional gene regions and encode for the four Ig(la...
journal_title:Leukemia
pub_type:
doi:
更新日期:1996-11-01 00:00:00
abstract::A total of 28 children and nine adults with relapsed T-ALL were analyzed for the configuration of their T-cell receptor (TCR) and TAL1 genes at diagnosis and relapse to evaluate their stability throughout the disease course. A total of 150 clonal TCR and TAL1 gene rearrangements were identified in the 37 patients at d...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403081
更新日期:2003-11-01 00:00:00
abstract::Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants. However, diagnostic dilemmas may arise in daily practice due to overlap of BL with subsets of other aggressive, mature B-cell ly...
journal_title:Leukemia
pub_type: 历史文章,杂志文章,评审
doi:10.1038/leu.2008.281
更新日期:2009-02-01 00:00:00
abstract::The notion that inherited predisposition contributes to the development of haematological malignancies is generally thought of as being a relatively new idea. However, Videbaek made a clear enunciation of such a hypothesis in 1947, from a study of tumour incidence in relatives of patients with different leukaemias. To...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403727
更新日期:2005-06-01 00:00:00
abstract::The stem cell leukaemia (SCL) gene is a member of the basic helix-loop-helix family of transcription factors and is essential for the development of all haematopoietic lineages. SCL is expressed in pluripotent haematopoietic stem cells and also following commitment to the erythroid, mast and megakaryocytic lineages. T...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401420
更新日期:1999-05-01 00:00:00
abstract::Chronic lymphocytic leukemia (CLL) cells could be undetectable by flow cytometry or polymerase chain reaction after sequential treatment with fludarabine and Campath-1H. Concern has been raised regarding the ability to mobilize sufficient peripheral blood progenitor cells (PBPCs) for autografting after purine analogue...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403190
更新日期:2004-01-01 00:00:00
abstract::Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 fro...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1038/leu.2015.281
更新日期:2016-03-01 00:00:00
abstract::Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...
journal_title:Leukemia
pub_type: 杂志文章,随机对照试验
doi:10.1038/s41375-018-0055-7
更新日期:2018-05-01 00:00:00
abstract::Kinase inhibitors block proliferative signals in BCR-ABL1+ leukemic cells, but their capacity to induce apoptosis is poorly understood. Initial studies suggested that very brief exposure to kinase inhibitors was sufficient to induce apoptosis in chronic myeloid leukemia (CML) cells. However, flaws in this experimental...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2014.156
更新日期:2015-01-01 00:00:00
abstract::Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the n...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-020-0804-2
更新日期:2020-05-01 00:00:00
abstract::Deletion and translocation involving the bands 11q14 and 11q21 have been detected in five patients with T cell acute lymphoblastic leukemia (ALL). The breakpoint on chromosome 11 was on the same band as that previously described in some acute nonlymphocytic leukemias: monocytic or myelomocytic. The existence of a new ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1989-08-01 00:00:00
abstract::Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-03-01 00:00:00
abstract::Chronic lymphocytic leukemia (CLL) consists of at least two major prognostic subgroups, characterized by different cellular and molecular markers. This observation sparked studies on the function and clinical importance of these markers. In order to address their function adequately, an efficient and reliable method f...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2405007
更新日期:2008-02-01 00:00:00
abstract::The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2017.257
更新日期:2018-02-01 00:00:00
abstract::Inhibitory proteins for Cdks (CKIs) are involved in cell cycle arrest induced by anti-mitotic factors, chemicals, or DNA damage in mammalian cells. High cell density also induces cell cycle arrest with unreplicated genomic DNA even in the presence of mitotic dose of the growth factors, termed contact inhibition. Altho...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun to provide direct...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-019-0703-6
更新日期:2020-03-01 00:00:00
abstract::Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2014.170
更新日期:2015-01-01 00:00:00
abstract::Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL). We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403847
更新日期:2005-08-01 00:00:00
abstract::Using the polymerase chain reaction and Southern blot analysis the expression was detected of a bcr-abl mRNA lacking abl exon a2. This was due to a corresponding unusual localization of the breakpoint in the c-abl gene and was seen in a patient with Philadelphia (Ph) chromosome positive chronic myelogeneous leukemia i...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-06-01 00:00:00
abstract::All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the treatment of patients (3), according to the results obtained by retinoic acid derivatives...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:
更新日期:1994-01-01 00:00:00
abstract::A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. Fifty...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1038/sj.leu.2401843
更新日期:2000-08-01 00:00:00
abstract::A novel erythroid cell line, RM10, was established from a long-term bone marrow culture of a patient with chronic myelogenous leukemia (CML). RM10 cells were positive for periodic acid Schiff (PAS), but negative for peroxidase and dual esterase. RM10 cells had la, pre B (CD10), myeloid (CD13, CD14, CD33) and erythroid...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-05-01 00:00:00
abstract::ATP-binding-cassette (ABC) transporters are evolutionary extremely well-conserved transmembrane proteins that are highly expressed in hematopoietic stem cells (HSCs). The physiological function in human stem cells is believed to be protection against genetic damage caused by both environmental and naturally occurring ...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2404859
更新日期:2007-10-01 00:00:00
abstract::The mechanism by which aplidine, a marine natural product in early clinical development as an anticancer agent, induces cell growth inhibition and apoptosis has been investigated in the human leukemia cell line MOLT-4. This cell line is characterized not only by the ability to secrete VEGF, but also for the presence o...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402788
更新日期:2003-01-01 00:00:00
abstract::A monoclonal antibody (17F11) was raised by immunization of a Balb/c mouse with leukemic blasts from a patient with acute non-lymphocytic leukemia (ANLL). This antibody recognizes most leukemic blasts of myeloid but not of lymphoid lineage and no peripheral blood cells. By screening NIH-3T3 fibroblasts transfected wit...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-10-01 00:00:00
abstract::Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant m...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0159-0
更新日期:2019-01-01 00:00:00
abstract::Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.313
更新日期:2014-05-01 00:00:00